Medication info
Mscpalm Extended-Release Tablet 12.5/50/750 mg (Empagliflozin, Sitagliptin, Metformin)

Mscpalm Extended-Release Tablet 12.5/50/750 mg (Empagliflozin, Sitagliptin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›750mg / 1 tabletSitagliptin Phosphate Hydrate›64.25mg / 1 tabletEmpagliflozin L-Proline›15.69mg / 1 tablet
Manufacturer / importer
Jongkundang Co., Ltd.
Appearance
Yellow, oval-shaped, double convex extended-release film-coated tablet
Packaging
30 tablets/bottle, 60 tablets/bottle
Approval status
Active

MFDS item code 202500914 · Approved 2025.04.16 · Insurance code 643309740

Summary

Main use
Improves blood glucose control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the recommended dose of this medicine is determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily dose of each component: empagliflozin 25 mg, sitagliptin 100 mg, and extended-release metformin hydrochloride 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this medicine once daily with a meal in the evening, with gradual dose titration. Patients taking this medicine as 25/100/1000 mg or 10/100/1000 mg extended-release tablets should take 1 tablet once daily. Patients taking this medicine as 12.5/50/750 mg or 5/50/750 mg extended-release tablets should take 2 tablets together once daily. For patients whose blood glucose is not adequately controlled with metformin and sitagliptin, the starting dose of this medicine should be empagliflozin 10 mg, sitagliptin 100 mg, and the metformin hydrochloride dose the patient was taking, or an appropriate dose therapeutically equivalent to it. If empagliflozin 10 mg is tolerated and additional glycemic control is needed, the dose of empagliflozin may be increased to 25 mg. For patients switching from combination therapy with empagliflozin, sitagliptin, and metformin to this medicine, use the dose of each component that the patient was previously taking. The safety and efficacy of this medicine have not been specifically evaluated in patients switching from other antihyperglycemic agents. Since such a change may result in changes in glycemic control, any change in treatment for patients with type 2 diabetes should be made under careful monitoring. To maintain its extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. This medicine may not dissolve completely and may be excreted in the stool. It is not known whether the material excreted in the stool contains the active ingredients of the medicine. If the patient repeatedly reports finding this medicine in the stool, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions). No dose adjustment is required in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2], this medicine may be used by adjusting the dose of metformin hydrochloride, one of its components, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000 mg. If creatinine clearance (CrCl) decreases to less than 45 mL/min or estimated glomerular filtration rate (eGFR) decreases to less than 45 mL/min/1.73m2, this medicine should be discontinued immediately.

Ingredients

Manufacturer
Jongkundang Co., Ltd.

Efficacy & effects

Improves blood glucose control in adults with type 2 diabetes mellitus

View approved original text

This medication is used in adult patients with type 2 diabetes to improve blood sugar control, complementing dietary and exercise regimens. The three components—empagliflozin, sitagliptin, and metformin—work together to effectively lower blood sugar levels. Therefore, this medication plays a significant role in the management of diabetes for patients.

How to take

Adult dose

For antidiabetic therapy, the recommended dose of this medicine is determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily dose of each component: empagliflozin 25 mg, sitagliptin 100 mg, and extended-release metformin hydrochloride 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this medicine once daily with a meal in the evening, with gradual dose titration. Patients taking this medicine as 25/100/1000 mg or 10/100/1000 mg extended-release tablets should take 1 tablet once daily. Patients taking this medicine as 12.5/50/750 mg or 5/50/750 mg extended-release tablets should take 2 tablets together once daily. For patients whose blood glucose is not adequately controlled with metformin and sitagliptin, the starting dose of this medicine should be empagliflozin 10 mg, sitagliptin 100 mg, and the metformin hydrochloride dose the patient was taking, or an appropriate dose therapeutically equivalent to it. If empagliflozin 10 mg is tolerated and additional glycemic control is needed, the dose of empagliflozin may be increased to 25 mg. For patients switching from combination therapy with empagliflozin, sitagliptin, and metformin to this medicine, use the dose of each component that the patient was previously taking. The safety and efficacy of this medicine have not been specifically evaluated in patients switching from other antihyperglycemic agents. Since such a change may result in changes in glycemic control, any change in treatment for patients with type 2 diabetes should be made under careful monitoring. To maintain its extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. This medicine may not dissolve completely and may be excreted in the stool. It is not known whether the material excreted in the stool contains the active ingredients of the medicine. If the patient repeatedly reports finding this medicine in the stool, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions). No dose adjustment is required in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2], this medicine may be used by adjusting the dose of metformin hydrochloride, one of its components, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000 mg. If creatinine clearance (CrCl) decreases to less than 45 mL/min or estimated glomerular filtration rate (eGFR) decreases to less than 45 mL/min/1.73m2, this medicine should be discontinued immediately.

Precautions

This medication may rarely cause serious allergic reactions due to the sitagliptin component. If any symptoms such as skin rash, difficulty in breathing, or swelling of the face or neck occur after taking the medication, it should be stopped immediately, and a doctor should be consulted. Additionally, sitagliptin may cause acute pancreatitis; hence, if symptoms like abdominal pain, vomiting, or persistent nausea develop after use, medical attention should be sought immediately. Although rare, metformin can cause a severe metabolic disorder known as lactic acidosis. Therefore, patients with impaired renal function, severe infections, dehydration, or heart failure should not use this medication. This medication should not be administered to patients with type 1 diabetes, acute metabolic acidosis, or moderate to severe renal impairment. If scheduled for surgery or in states of severe infection or trauma, it is advisable to temporarily discontinue this medication and resume after stabilization. Patients with decreased kidney function should undergo regular kidney function tests, and the medication should not be taken if kidney function is significantly compromised. This medication carries a risk of hypoglycemia; therefore, especially when taken with other hypoglycemic agents, blood glucose levels should be monitored regularly, and symptoms of hypoglycemia should be observed closely. Moreover, this medication may increase the risk of genital and urinary tract infections; prompt treatment should be sought if symptoms of infection occur. Fluid loss or dehydration can occur; thus, in cases of vomiting or diarrhea that impede fluid intake, it is advisable to temporarily stop the medication and consult a doctor. It is safe for pregnant women or those with placental insufficiency to avoid using this medication. Regular blood tests and health status monitoring are needed during the course of this medication, and any abnormal symptoms should be reported to healthcare professionals immediately.

Side effects

  • Hypersensitivity
  • anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • exfoliative skin disease
  • acute pancreatitis
  • lactic acidosis
  • influenza
  • nasopharyngitis
  • perianal abscess
Show 156 more
  • perforated appendicitis
  • cervicitis
  • coronavirus infection
  • otitis media
  • periodontitis
  • tooth abscess
  • vaginal infection
  • dyspepsia
  • abdominal pain
  • upper abdominal pain
  • diarrhea
  • dry mouth
  • alcoholic gastritis
  • erosive gastritis
  • hematemesis
  • hemorrhoids
  • nausea
  • chest pain
  • weakness
  • fatigue
  • increased blood glucose
  • weight loss
  • increased serum creatine phosphokinase
  • eyelid twitching
  • diabetic retinopathy
  • keratitis
  • vitreous hemorrhage
  • bladder transitional cell carcinoma
  • prostate cancer
  • renal cell carcinoma
  • right atrial block
  • left ventricular hypertrophy
  • hyperglycemia
  • hypoglycemia
  • vulvar pruritus
  • diaphoresis
  • dermatitis
  • bile duct obstruction
  • forearm fracture
  • headache
  • insomnia
  • frequent urination
  • sleep apnea syndrome
  • removal of artificial fixtures
  • vomiting
  • change in bowel habits
  • colitis
  • dental caries
  • gastroenteritis
  • external auditory canal inflammation
  • cataract
  • borderline glaucoma
  • endocrine ophthalmopathy
  • arthralgia
  • lumbar spinal stenosis
  • spinal canal stenosis
  • cough
  • eosinophilic bronchitis
  • oropharyngeal pain
  • contusion
  • foot fracture
  • radiculopathy
  • thalamic infarction
  • breast mass
  • keloid scar
  • rash
  • aortic aneurysm
  • hypotension
  • ventricular ectopic contraction
  • gill pouch
  • vomiting
  • upper abdominal pain
  • gastric ulcer
  • ischemic colitis
  • colonic bleeding
  • soft tissue infection
  • appendiceal abscess
  • meningitis
  • chronic otitis media
  • peritonsillar abscess
  • pneumonia
  • pulmonary tuberculosis
  • acute pyelonephritis
  • sepsis
  • subcutaneous abscess
  • tubo-ovarian abscess
  • vestibular neuritis
  • acute pyelonephritis
  • headache
  • cerebral infarction
  • intracranial aneurysm
  • fever
  • vascular stent stenosis
  • vascular stent thrombosis
  • increased alanine aminotransferase
  • increased aspartate aminotransferase
  • ureterolithiasis
  • acute kidney injury
  • cervicitis
  • hyperglycemia
  • hyponatremia
  • diabetic foot
  • back pain
  • glaucoma
  • pathological myopia
  • retinal detachment
  • retinal vein occlusion
  • rhegmatogenous retinal detachment
  • limb injury
  • traffic accident
  • splenic injury
  • sternum fracture
  • angina
  • Prinzmetal angina
  • coronary artery disease
  • deep vein thrombosis
  • acute cholecystitis
  • autoimmune hepatitis
  • cholelithiasis
  • unstable angina
  • anxiety
  • depression
  • sleep disorders
  • acute cholecystitis
  • hepatitis
  • otalgia
  • positional vertigo
  • dizziness
  • chest discomfort
  • chest pain
  • weakness
  • weight loss
  • vulvar pruritus
  • genital pruritus
  • dyslipidemia
  • hyperglycemia
  • lumbar spinal stenosis
  • back pain
  • diabetic retinopathy
  • dry eyes
  • cough
  • dyspnea
  • unstable angina
  • hypertension
  • hypoglycemia
  • urticaria
  • angioedema
  • thrombocytopenia
  • rhabdomyolysis
  • severe and disabling arthralgia
  • vesicular pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture. It is recommended to keep it at room temperature between 1 to 30 degrees Celsius.

Appearance and packaging

Appearance

Yellow, oval-shaped, double convex extended-release film-coated tablet

Package unit

30 tablets/bottle, 60 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.